New hope for aplastic anemia: drug combo aims to cut transfusions
NCT ID NCT07548671
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding enarodustat to standard cyclosporine treatment helps people with transfusion-dependent non-severe aplastic anemia. The study will enroll 90 newly diagnosed adults who cannot have a stem cell transplant. The goal is to see if the combination improves blood counts and reduces the need for transfusions compared to cyclosporine alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enarodustat and cyclosporine
- What this could lead to
- If successful, this combination could become a new standard treatment for transfusion-dependent non-severe aplastic anemia, reducing or eliminating the need for blood transfusions.
- What could go wrong
- This is a Phase 3 trial, but it has not yet started recruiting. The combination may not be more effective than cyclosporine alone, and both drugs carry risks like kidney problems or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.